How much does a box of filgotinib cost? What is its market pricing and drug cost profile?

Filgotinib is a new type of oral JAK1 selective inhibitor, mainly used to treat immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The drug, jointly developed by Galapagos and Gilead, has attracted clinical attention due to its good efficacy and relatively low adverse reactions. However, as of now, filgotinib has not been approved for marketing by the State Food and Drug Administration in mainland China, which means that patients are temporarily unable to purchase the drug directly in domestic hospitals or pharmacies.

Since it has not yet been launched in China, domestic patients who need to use filgotinib can only rely on overseas channels to purchase it, which also results in differences in drug prices. Currently, the original version of filgotinib sold in Europe and other regions is usually 200mg*30 tablets, which is a standard dosage for one month. Its price is relatively expensive, with each box costing about more than 10,000 yuan. This price is a significant expense for patients who take the medicine for a long time, especially when it is not included in the scope of medical insurance reimbursement, and the financial burden increases significantly.

In order to alleviate the financial pressure on some patients, some overseas pharmaceutical companies have also launched generic versions of filgotinib. One of the more well-known sources of generics is Lucius Pharmaceutical Factory in Laos. The generic version of filgotinib produced by this factory is 100mg*30 tablets, and each box sells for about 900 yuan. Although the specifications are slightly different, from the perspective of cost performance, generic drugs are more affordable and suitable for long-term use by patients with limited financial conditions. It should be noted that when choosing generic drugs, patients should ensure that they come from regular sources and use them under the guidance of professional doctors to ensure efficacy and safety.

The market pricing of filgotinib is closely related to its research and development costs, clinical efficacy and market demand. As an oral inhibitor targeting JAK1, it has shown good efficacy in the treatment of multiple autoimmune diseases, especially in reducing joint inflammation, improving dysfunction and improving quality of life. Compared with other JAK inhibitors (such as tofacitinib, uppatinib, etc.), filgotinib is considered to have lower risks of infection, thrombosis, etc. due to its high selectivity for JAK1, which is also a factor in its higher pricing.

Generally speaking, filgotinib is a high-end targeted drug in the international market. Its original version is more expensive, while the generic version provides a more economical alternative. The current problem faced by Chinese patients is the lack of official channels for purchasing medicines, and they need to obtain them through formal overseas platforms, pharmaceutical service agencies or overseas medical resources. In addition, because it is not marketed in China, the drug has not yet been included in the national medical insurance system, and there are no unified domestic clinical application guidelines. Patients should undergo individualized evaluation by a rheumatology and immunology department or gastroenterologist before use.

In the future, if filgotinib can be approved for marketing in China, the price may gradually be rationalized and it may be included in the medical insurance catalog, thereby reducing the burden on patients and expanding drug accessibility. Currently, a variety of domestic JAK inhibitors with similar mechanisms are on the market, such as tofacitinib, baricitinib, upadatinib, etc., which to a certain extent also provide treatment options for patients. However, filgotinib remains a potentially important alternative for patients who do not respond well to existing drugs, and its clinical value cannot be ignored.

Reference materials:https://go.drugbank.com/drugs/DB14845